APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-VEGF Therapy for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-VEGF Therapy for Cancer Market Outlook and Growth Opportunities 2026

27 December 2025199 pages

Choose your research edition.

Industry ResearchAnti-VEGF Therapy for Cancer Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-VEGF Therapy for Cancer Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Anti-VEGF Therapy for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-VEGF Therapy for Cancer Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-VEGF Therapy for Cancer Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-VEGF Therapy for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-VEGF Therapy for Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-VEGF Therapy for Cancer market include Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Sanofi, Roche, Pfizer, Novartis, Janssen Biotech, Exelixis and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anti-VEGF Therapy for Cancer market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-VEGF Therapy for Cancer and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-VEGF Therapy for Cancer revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-VEGF Therapy for Cancer market.

Anti-VEGF Therapy for Cancer Segment by Company

Chia Tai Tianqing

Jiangsu Hengrui Pharmaceuticals

Sanofi

Roche

Pfizer

Novartis

Janssen Biotech

Exelixis

Eli Lilly

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca

Anti-VEGF Therapy for Cancer Segment by Type

VEGF Inhibitors

VEGFR Inhibitors

Anti-VEGF Therapy for Cancer Segment by Application

Non-small Cell Lung Cancer

Cervical Cancer

Colorectal Cancer

Renal Cell Carcinoma

Medullary Thyroid Cancer

Other

Anti-VEGF Therapy for Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-VEGF Therapy for Cancer status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anti-VEGF Therapy for Cancer key companies, revenue, market share, and recent developments.

3. To split the Anti-VEGF Therapy for Cancer breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anti-VEGF Therapy for Cancer market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-VEGF Therapy for Cancer significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-VEGF Therapy for Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Therapy for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Therapy for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Therapy for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-VEGF Therapy for Cancer industry.

Chapter 3: Detailed analysis of Anti-VEGF Therapy for Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anti-VEGF Therapy for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anti-VEGF Therapy for Cancer in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-VEGF Therapy for Cancer Industry Trends Table 2. Anti-VEGF Therapy for Cancer Industry Drivers Table 3. Anti-VEGF Therapy for Cancer Industry Opportunities and Challenges Table 4. Anti-VEGF Therapy for Cancer Industry Restraints Table 5. Global Anti-VEGF Therapy for Cancer Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-VEGF Therapy for Cancer Revenue Share by Company (2021-2026) Table 7. Global Anti-VEGF Therapy for Cancer Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anti-VEGF Therapy for Cancer Key Company Manufacturing Base & Headquarters Table 9. Global Anti-VEGF Therapy for Cancer Company, Product Type & Application Table 10. Global Anti-VEGF Therapy for Cancer Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anti-VEGF Therapy for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of VEGF Inhibitors Table 15. Significant Companies of VEGFR Inhibitors Table 16. Global Anti-VEGF Therapy for Cancer Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Anti-VEGF Therapy for Cancer Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Anti-VEGF Therapy for Cancer Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Anti-VEGF Therapy for Cancer Sales Value Share by Type (2021-2026) Table 20. Global Anti-VEGF Therapy for Cancer Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Non-small Cell Lung Cancer Table 22. Significant Companies of Cervical Cancer Table 23. Significant Companies of Colorectal Cancer Table 24. Significant Companies of Renal Cell Carcinoma Table 25. Significant Companies of Medullary Thyroid Cancer Table 26. Significant Companies of Other Table 27. Global Anti-VEGF Therapy for Cancer Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Anti-VEGF Therapy for Cancer Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Anti-VEGF Therapy for Cancer Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Anti-VEGF Therapy for Cancer Sales Value Share by Application (2021-2026) Table 31. Global Anti-VEGF Therapy for Cancer Sales Value Share by Application (2027-2032) Table 32. Global Anti-VEGF Therapy for Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Anti-VEGF Therapy for Cancer Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Anti-VEGF Therapy for Cancer Sales Value Share by Region (2021-2026) Table 35. Global Anti-VEGF Therapy for Cancer Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Anti-VEGF Therapy for Cancer Sales Value Share by Region (2027-2032) Table 37. Global Anti-VEGF Therapy for Cancer Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Anti-VEGF Therapy for Cancer Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Anti-VEGF Therapy for Cancer Sales Value Market Share by Country (2021-2026) Table 40. Global Anti-VEGF Therapy for Cancer Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Anti-VEGF Therapy for Cancer Sales Value Market Share by Country (2027-2032) Table 42. Chia Tai Tianqing Company Information Table 43. Chia Tai Tianqing Business Overview Table 44. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Portfolio Table 46. Chia Tai Tianqing Recent Development Table 47. Jiangsu Hengrui Pharmaceuticals Company Information Table 48. Jiangsu Hengrui Pharmaceuticals Business Overview Table 49. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Portfolio Table 51. Jiangsu Hengrui Pharmaceuticals Recent Development Table 52. Sanofi Company Information Table 53. Sanofi Business Overview Table 54. Sanofi Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Sanofi Anti-VEGF Therapy for Cancer Product Portfolio Table 56. Sanofi Recent Development Table 57. Roche Company Information Table 58. Roche Business Overview Table 59. Roche Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Roche Anti-VEGF Therapy for Cancer Product Portfolio Table 61. Roche Recent Development Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Pfizer Anti-VEGF Therapy for Cancer Product Portfolio Table 66. Pfizer Recent Development Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis Anti-VEGF Therapy for Cancer Product Portfolio Table 71. Novartis Recent Development Table 72. Janssen Biotech Company Information Table 73. Janssen Biotech Business Overview Table 74. Janssen Biotech Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Janssen Biotech Anti-VEGF Therapy for Cancer Product Portfolio Table 76. Janssen Biotech Recent Development Table 77. Exelixis Company Information Table 78. Exelixis Business Overview Table 79. Exelixis Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Exelixis Anti-VEGF Therapy for Cancer Product Portfolio Table 81. Exelixis Recent Development Table 82. Eli Lilly Company Information Table 83. Eli Lilly Business Overview Table 84. Eli Lilly Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Eli Lilly Anti-VEGF Therapy for Cancer Product Portfolio Table 86. Eli Lilly Recent Development Table 87. Eisai Company Information Table 88. Eisai Business Overview Table 89. Eisai Anti-VEGF Therapy for Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Eisai Anti-VEGF Therapy for Cancer Product Portfolio Table 91. Eisai Recent Development Table 92. Boehringer Ingelheim Company Information Table 93. Boehringer Ingelheim Business Overview Table 94. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Portfolio Table 96. Boehringer Ingelheim Recent Development Table 97. Bayer Company Information Table 98. Bayer Business Overview Table 99. Bayer Anti-VEGF Therapy for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Bayer Anti-VEGF Therapy for Cancer Product Portfolio Table 101. Bayer Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca Anti-VEGF Therapy for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. AstraZeneca Anti-VEGF Therapy for Cancer Product Portfolio Table 106. AstraZeneca Recent Development Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Anti-VEGF Therapy for Cancer Product Image Figure 2. Global Anti-VEGF Therapy for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-VEGF Therapy for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-VEGF Therapy for Cancer Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. VEGF Inhibitors Image Figure 8. VEGFR Inhibitors Image Figure 9. Global Anti-VEGF Therapy for Cancer Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Anti-VEGF Therapy for Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Anti-VEGF Therapy for Cancer Sales Value Share by Type (2021-2032) Figure 12. Non-small Cell Lung Cancer Image Figure 13. Cervical Cancer Image Figure 14. Colorectal Cancer Image Figure 15. Renal Cell Carcinoma Image Figure 16. Medullary Thyroid Cancer Image Figure 17. Other Image Figure 18. Global Anti-VEGF Therapy for Cancer Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Anti-VEGF Therapy for Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Anti-VEGF Therapy for Cancer Sales Value Share by Application (2021-2032) Figure 21. Global Anti-VEGF Therapy for Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Anti-VEGF Therapy for Cancer Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Anti-VEGF Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 24. North America Anti-VEGF Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Anti-VEGF Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Anti-VEGF Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Anti-VEGF Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Anti-VEGF Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Anti-VEGF Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 30. South America Anti-VEGF Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Anti-VEGF Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Anti-VEGF Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • VEGF Inhibitors
  • VEGFR Inhibitors
Applications
  • Non-small Cell Lung Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Renal Cell Carcinoma
  • Medullary Thyroid Cancer
  • Other
Companies covered
  • Chia Tai Tianqing
  • Jiangsu Hengrui Pharmaceuticals
  • Sanofi
  • Roche
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eli Lilly
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-VEGF Therapy for Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-VEGF Therapy for Cancer Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anti-VEGF Therapy for Cancer Market Dynamics
  1. 2.1 Anti-VEGF Therapy for Cancer Industry Trends
  2. 2.2 Anti-VEGF Therapy for Cancer Industry Drivers
  3. 2.3 Anti-VEGF Therapy for Cancer Industry Opportunities and Challenges
  4. 2.4 Anti-VEGF Therapy for Cancer Industry Restraints
3 Anti-VEGF Therapy for Cancer Market by Company
  1. 3.1 Global Anti-VEGF Therapy for Cancer Company Revenue Ranking in 2025
  2. 3.2 Global Anti-VEGF Therapy for Cancer Revenue by Company (2021-2026)
  3. 3.3 Global Anti-VEGF Therapy for Cancer Company Ranking (2024-2026)
  4. 3.4 Global Anti-VEGF Therapy for Cancer Company Manufacturing Base and Headquarters
  5. 3.5 Global Anti-VEGF Therapy for Cancer Company Product Type and Application
  6. 3.6 Global Anti-VEGF Therapy for Cancer Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anti-VEGF Therapy for Cancer Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anti-VEGF Therapy for Cancer Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anti-VEGF Therapy for Cancer Market by Type
  1. 4.1 Anti-VEGF Therapy for Cancer Type Introduction
  2. 4.1.1 VEGF Inhibitors
  3. 4.1.2 VEGFR Inhibitors
  4. 4.2 Global Anti-VEGF Therapy for Cancer Sales Value by Type
  5. 4.2.1 Global Anti-VEGF Therapy for Cancer Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-VEGF Therapy for Cancer Sales Value by Type (2021-2032)
  7. 4.2.3 Global Anti-VEGF Therapy for Cancer Sales Value Share by Type (2021-2032)
5 Anti-VEGF Therapy for Cancer Market by Application
  1. 5.1 Anti-VEGF Therapy for Cancer Application Introduction
  2. 5.1.1 Non-small Cell Lung Cancer
  3. 5.1.2 Cervical Cancer
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Renal Cell Carcinoma
  6. 5.1.5 Medullary Thyroid Cancer
  7. 5.1.6 Other
  8. 5.2 Global Anti-VEGF Therapy for Cancer Sales Value by Application
  9. 5.2.1 Global Anti-VEGF Therapy for Cancer Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Anti-VEGF Therapy for Cancer Sales Value by Application (2021-2032)
  11. 5.2.3 Global Anti-VEGF Therapy for Cancer Sales Value Share by Application (2021-2032)
6 Anti-VEGF Therapy for Cancer Regional Value Analysis
  1. 6.1 Global Anti-VEGF Therapy for Cancer Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-VEGF Therapy for Cancer Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anti-VEGF Therapy for Cancer Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anti-VEGF Therapy for Cancer Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-VEGF Therapy for Cancer Sales Value (2021-2032)
  7. 6.3.2 North America Anti-VEGF Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anti-VEGF Therapy for Cancer Sales Value (2021-2032)
  10. 6.4.2 Europe Anti-VEGF Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anti-VEGF Therapy for Cancer Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anti-VEGF Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anti-VEGF Therapy for Cancer Sales Value (2021-2032)
  16. 6.6.2 South America Anti-VEGF Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anti-VEGF Therapy for Cancer Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anti-VEGF Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
7 Anti-VEGF Therapy for Cancer Country-level Value Analysis
  1. 7.1 Global Anti-VEGF Therapy for Cancer Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-VEGF Therapy for Cancer Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anti-VEGF Therapy for Cancer Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anti-VEGF Therapy for Cancer Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anti-VEGF Therapy for Cancer Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anti-VEGF Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anti-VEGF Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing
  2. 8.1.1 Chia Tai Tianqing Company Information
  3. 8.1.2 Chia Tai Tianqing Business Overview
  4. 8.1.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Recent Developments
  7. 8.2 Jiangsu Hengrui Pharmaceuticals
  8. 8.2.1 Jiangsu Hengrui Pharmaceuticals Company Information
  9. 8.2.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  10. 8.2.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Portfolio
  12. 8.2.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Anti-VEGF Therapy for Cancer Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Anti-VEGF Therapy for Cancer Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Anti-VEGF Therapy for Cancer Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Anti-VEGF Therapy for Cancer Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Janssen Biotech
  38. 8.7.1 Janssen Biotech Company Information
  39. 8.7.2 Janssen Biotech Business Overview
  40. 8.7.3 Janssen Biotech Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Janssen Biotech Anti-VEGF Therapy for Cancer Product Portfolio
  42. 8.7.5 Janssen Biotech Recent Developments
  43. 8.8 Exelixis
  44. 8.8.1 Exelixis Company Information
  45. 8.8.2 Exelixis Business Overview
  46. 8.8.3 Exelixis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Exelixis Anti-VEGF Therapy for Cancer Product Portfolio
  48. 8.8.5 Exelixis Recent Developments
  49. 8.9 Eli Lilly
  50. 8.9.1 Eli Lilly Company Information
  51. 8.9.2 Eli Lilly Business Overview
  52. 8.9.3 Eli Lilly Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly Anti-VEGF Therapy for Cancer Product Portfolio
  54. 8.9.5 Eli Lilly Recent Developments
  55. 8.10 Eisai
  56. 8.10.1 Eisai Company Information
  57. 8.10.2 Eisai Business Overview
  58. 8.10.3 Eisai Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eisai Anti-VEGF Therapy for Cancer Product Portfolio
  60. 8.10.5 Eisai Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Anti-VEGF Therapy for Cancer Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Anti-VEGF Therapy for Cancer Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst